Brainstorm cell therapeutics announces outcome of fda meeting on nurown® in als

Meeting provided a clear path for planned phase 3b trial new york , dec. 7, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the completion of a productive meeting with the u.s. food and drug administration (fda) to discuss nurown®, its investigational treatment for amyotrophic lateral sclerosis (als). the primary objective of the meeting was to discuss key considerations for a special protocol assessment (spa) for a planned phase 3b registrational trial for nurown.
BCLI Ratings Summary
BCLI Quant Ranking